ABT vs DXCM
Abbott Laboratories (ABT) and Dexcom (DXCM) compared side by side. Abbott Laboratories (ABT) is larger, with a market cap of $179.4B versus $29.4B for Dexcom, about 6.1 times the size. On trailing earnings, DXCM is cheaper at 30.9x versus 38.6x for ABT.
Head to head
| Metric | ABT | DXCM |
|---|---|---|
| Market cap | $179.4B | $29.4B |
| P/E (TTM) | 38.6x | 30.9x |
| Forward P/E | 17.4x | 25.0x |
| Revenue (TTM) | $48.2B | $5.0B |
| Revenue growth | 14.5% | 13.1% |
| Gross margin | 57.1% | 62.5% |
| Operating margin | 11.3% | 24.3% |
| Free cash flow | $7.4B | $1.4B |
| Dividend yield | 2.43% | None |
| 1-year return | -15.9% | +9.7% |
| 5-year return (annual) | -2.0% | -11.3% |
| Max drawdown | -46% | -95% |
| FI Handbook grade | C+ | B+ |
Highlighted: the stronger figure on metrics where higher or lower is clearly better.
Growth of $10,000 (5 years, price only)
ABT vs DXCM FAQ
Which is bigger, ABT or DXCM?
Abbott Laboratories (ABT) is larger, with a market cap of $179.4B versus $29.4B for Dexcom, about 6.1 times the size.
Is ABT or DXCM cheaper?
On trailing earnings, DXCM is cheaper at 30.9x versus 38.6x for ABT. A lower P/E can reflect slower expected growth, so compare growth and margins too.
Which stock performed better over the past year, ABT or DXCM?
DXCM returned +9.7% over the past year including dividends, versus -15.9% for ABT, through October 23, 2026.
Which pays a higher dividend, ABT or DXCM?
ABT yields 2.43%; DXCM does not pay a dividend.
Full pages: Abbott Laboratories · Dexcom